Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 28143


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Biotechnology
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28143

License Grant
The Licensee entered into an exclusive Product Development and Patent License Agreement with the Licensor to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes.
Field of Use
Alpha emitting isotopes may result in more efficient leukemia cell killing without the toxicity of intensive chemotherapy.

IPSCIO Record ID: 1010

License Grant
Licensor hereby grants, and Licensee herby accepts, an exclusive, worldwide license, including the right to grant sublicenses, under the Licensor's Patent Rights and Licenso's Technical Information, to research, develop, make, have made, import, market, promote, use, sell, offer to sell and have sold Licensed Products in the Field.  Licensee shall have the right to grant sublicenses of its rights.
License Property
Licensor owns certain patents and related patent applications related to humanized antibodies and antibody humanization technology.
Licensor has certain rights to a humanized antibody directed against the CD33 antigen and designated by Licensor as HuM195.

HuM195 Antibody means the humanized version of the m195 antibody directed against the CD33 antigen.

Patent No. 5,585,089, Humanized Immunoglobulins
Patent No. 5,693,761, Polynucleotides Encoding Improved Humanized Immunoglobulins
Patent No. 5,693,762, Humanized Immunoglobulins
Patent No. 6,180, 370 Humanized Immunoglobulins and Method of Making the Same

Field of Use
Field means any form or derivative of the HuM195 Antibody conjugated with Actinium -225 or other alpha emitting radioisotopes (the HuM195 Antibody conjugate), including without limitation conjugates with biospecific, less than full-length antibody forms such as Fv, Fab, and F(ab), single-chain antibodies and hybrid antibodies, provided however, that the Field shall not include the unconjugated HuM195 Antibody (except as delivered as part of a mixture with the HuM195 Antibody Conjugate and delivered as a single therapy), the HuM195 Antibody conjugated with any radionuclide other than Actinium-225 or other alpha emitters, or the HuM105 Antibody conjugated with a peptide or small molecule toxin.

The Licensee secured exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes.

Alpha particles are of considerable interest for radioimmunotherapy applications since their short range in soft tissue is limited to only a few cell diameters. The delivery of such high energy in such a small volume, or high-linear-energy-transfer (LET), makes alpha particles especially well suited for targeting micrometastatic disease and single tumor cells such as leukemia and other blood-borne disease.

IPSCIO Record ID: 1351

License Grant
Licensor, a non-profit cancer treatment and research institution, hereby grants to Licensee an exclusive license in the field under Licensor Patents and Licensor Know-How to develop, use, make, have made, market, offer to sell, sell and import for sale Licensed Products in the Territory with the right to sublicense.
Licensee shall have the right to grant sublicenses under the license to employ Affiliates and Third Parties.
License Property
Licensee and Licensor wish to cooperate in optimizing the development and commercialization of targeted Ac-225 and/or Bi-213 as therapeutics by API.

SK979 – Targeted alpha particle therapy with DOTA-based complexes of Ac225 – US Provisional application number 60/232,909.
SK933 – Liposome encapsulation of Ac225 – US Provisional application number 60/212,186.
SK352 – Alpha emitting constructs and used thereof – US Provisional application number 60/086,772.
SK712 – Bi-213 Generator and used thereof – US Provisional application number 60/079,902.

Field of Use
Licensed Products shall mean a product, that is covered by a valid claim of an Licensor patent or which incorporates and utilizes Licensor  know-how, prepared for therapeutic use comprising the radionuclide Ac-225 or Bi-213, and one or more targeting, delivery, attachment or carrier moieties including but not limited to monoclonal or other antibodies, antibody fragments or antibody derivatives, receptor ligands, proteins, peptides, liposomes, small molecules, or chemical chelators.

The field shall mean all therapeutic use of Licensed Products in humans and animals.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.